Use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds in the design of potent inhibitors of serine proteinases

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 5, 1998, Pages 539-544

  Kuang, Rongze ^a   Venkataraman, Radhika ^a   Ruan, Sumei ^a   Groutas, William C ^a  

^a WICHITA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,5 THIADIAZOLIDIN 3 ONE 1,1 DIOXIDE; ELASTASE; ENZYME INHIBITOR; ISOTHIAZOLIDIN 3 ONE 1,1 DIOXIDE; PHOSPHATE; PROTEINASE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; LEUKOCYTE; NONHUMAN;

BINDING SITES; DRUG DESIGN; HUMANS; KINETICS; LEUKOCYTE ELASTASE; MODELS, MOLECULAR; SERINE PROTEINASE INHIBITORS; THIADIAZOLES;

EID: 0032478061     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00067-5     Document Type: Article

References (21)

1. 1. Barrett, A. J. Agents Actions 1994, 43, 194.
2. 2. Matrisian, L. M. Bioessays 1992, 14, 455.
3. 3. Crystal, R. J. J. Clin Invest. 1990, 85, 1343.
4. 4. Travis, J.; Pike, R.; Inamura, T.; Potempa, J. Am. J. Respir. Crit. Care Med. 1994, 150, S123.
5. 5. Wiedow, O.; Wiese, F.; Christophers, E. Arch. Dermatol. Res. 1995, 287, 632.
6. 6. Yang, B. C.; Williams, J. C.; Mehta, J. L. J. Cardiovasc. Pharmacol. Therapeut. 1996, 1, 31.
7. 7. Birrer, R.; McElvaney, N. G.; Rudeberg, A.; Sommer, C. W.; Liechti-Gallati, S.; Kraemer, R.; Hubbard, R.; Crystal, R. G. Am. J. Respir. Crit. Care Med. 1994, 150, 207.
8. 8. Janusz, M. J.; Doherty, N. S. J. Immunol. 1991, 146, 3922.
9. 9. Abrahamson, D. R.; Irvin, M. H.; Blackburn, W. D.; Heck, L. W. Am. J. Pathol. 1990, 136, 1267.
10. 10. Okada, Y.; Nakanishi, Y. FEBS Lett. 1989, 249, 353.
11. 11. Snider, G. L. Drug Dev. Res. 1987, 10, 235.
12. 12. Groutas, W. C.; Kuang, R.; Venkataraman, R.; Epp, J. B.; Ruan, S.; Prakash, O. Biochemistry 1997, 36, 4739 and references cited therein.
13. 13. Groutas, W. C.; Chong, L. S.; Venkataraman, R. Biochem. Biophys. Res.Comm. 1993, 197, 730.
14. 14. All new compounds were characterized by full spectroscopic data.
15. 15. Morrison, J. F.; Walsh, C. T. Adv. Enzymol. 1988, 61, 201.
16. 16. Bode, W.; Wei, A-Z.; Huber, R.; Meyer, E. F.; Travis, J.; Neumann, S. EMBO J. 1986, 5, 2453.
17. 17. (a) For the first use of the phosphonate leaving group in saccharin-based inhibitors of HLE, see Desai, R. C.; Court, J. C.; Ferguson, E.; Gordon, R. J.; Hlasta, D. J. J. Med. Chem. 1995, 38, 1571;
18. (b) Court, J. J.; Desai, R. J., USA Patent 5,541,168, July 30, 1996 (CA: 125:143004).
19. 18. Edwards, P. D.; Bernstein, P. R. Med. Res. Revs. 1994, 14, 127.
20. 19. Bode, W.; Meyer, E. F.; Powers, J. C. Biochemistry 1989, 28, 1951.
21. 20. Hof, P.; Mayr, I.; Huber, R.; Korzus, E.; Potempa, J.; Travis, J.; Powers, J. C.; Bode, W. EMBO J. 1996, 15, 5481.